Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Kausik K. Ray; R. Scott Wright; David Kallend; Wolfgang Köenig; Lawrence A. Leiter; Frederick J. Raal; Jenna A. Bisch; Tara Richardson; Mark Jaros; Peter Wijngaard; John J.P. Kastelein

doi:10.1056/nejmoa1912387

Abstract

Reductions in LDL cholesterol levels of approximately 50% were obtained with inclisiran, administered subcutaneously every 6 months. More injection-site adverse events occurred with inclisiran than with placebo. (Funded by the Medicines Company; ORION-10 and ORION-11 ClinicalTrials.gov numbers, NCT03399370 and NCT03400800.).

Keywords

Ldl cholesterolPhase (matter)CholesterolInternal medicineMedicineChemistry

Affiliated Institutions

Related Publications

Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study

Peter H. Jones , John A. Farmer , Michael D. Cressman +12 more

Abstract This multicenter, double‐blind, placebo‐controlled study was conducted to evaluate dose‐response effects and safety of once‐daily administration of pravastatin, a new i...

1991 Clinical Cardiology 65 citations

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

Salim Yusuf , Eva Lonn , Prem Pais +29 more

BACKGROUND: Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of c...

2016 New England Journal of Medicine 367 citations

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

Curt D. Furberg , Hadie Adams , William B. Applegate +7 more

BACKGROUND HMG CoA reductase inhibitors (or statins), a new class of lipid-lowering compounds, have raised expectations for more widespread use than that of the older lipid-lowe...

1994 Circulation 875 citations

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

S. Féasson

Throughout the usual LDL cholesterol range in Western populations, lower blood concentrations are associated with lower cardiovascular disease risk. In such populations, therefo...

2002 The Lancet 6959 citations

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa , George Lau , Masatoshi Kudo +28 more

BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion reg...

2022 NEJM Evidence 1193 citations

Publication Info

Year: 2020
Type: article
Volume: 382
Issue: 16
Pages: 1507-1519
Citations: 1367
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1367

OpenAlex

Cite This

APA Style

                            
                                
                                    Kausik K. Ray, 
                                
                                    R. Scott Wright, 
                                
                                    David Kallend
                                
                                et al.
                            
                            (2020). 
                            Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. 
                            New England Journal of Medicine
                            , 382
                            (16)
                            , 1507-1519.
                            https://doi.org/10.1056/nejmoa1912387
                        

Identifiers

DOI: 10.1056/nejmoa1912387